1: Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam
MA. Formulation and characterization of novel soft nanovesicles for enhanced
transdermal delivery of eprosartan mesylate. Saudi Pharm J. 2017
Nov;25(7):1040-1046. doi: 10.1016/j.jsps.2017.01.006. Epub 2017 Feb 2. PubMed
PMID: 29158713; PubMed Central PMCID: PMC5681305.
<br>
2: Ahad A, Raish M, Ahmad A, Al-Jenoobi FI, Al-Mohizea AM. Eprosartan mesylate
loaded bilosomes as potential nano-carriers against diabetic nephropathy in
streptozotocin-induced diabetic rats. Eur J Pharm Sci. 2018 Jan 1;111:409-417.
doi: 10.1016/j.ejps.2017.10.012. Epub 2017 Oct 10. PubMed PMID: 29030177.
<br>
3: Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam
MA. Formulation and characterization of Phospholipon 90 G and tween 80 based
transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol.
2017 May 26:1-7. doi: 10.1080/10837450.2017.1330345. [Epub ahead of print] PubMed
PMID: 28504046.
<br>
4: Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam
MA. Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopol(®)
gel under Dermaroller(®) on rats with methyl prednisolone acetate-induced
hypertension. Biomed Pharmacother. 2017 May;89:177-184. doi:
10.1016/j.biopha.2017.01.164. Epub 2017 Feb 24. PubMed PMID: 28237913.
<br>
5: Dangre P, Gilhotra R, Dhole S. Formulation and statistical optimization of
self-microemulsifying drug delivery system of eprosartan mesylate for improvement
of oral bioavailability. Drug Deliv Transl Res. 2016 Oct;6(5):610-21. doi:
10.1007/s13346-016-0318-7. PubMed PMID: 27465619.
<br>
6: Kalariya PD, Kumar Talluri MV, Gaitonde VD, Devrukhakar PS, Srinivas R.
Quality by design: a systematic and rapid liquid chromatography and mass
spectrometry method for eprosartan mesylate and its related impurities using a
superficially porous particle column. J Sep Sci. 2014 Aug;37(16):2160-71. doi:
10.1002/jssc.201301364. Epub 2014 Jul 10. PubMed PMID: 24913516.
<br>
7: Anandakumar K, Santhi DV, Jothieswari D, Subathrai R, Vetrichelvan T.
Development and Validation of a UV Spectrophotometric Method for the Simultaneous
Estimation of Eprosartan Mesylate and Hydrochlorothiazide in Bulk and
Formulations. Indian J Pharm Sci. 2011 Sep;73(5):569-72. doi:
10.4103/0250-474X.99017. PubMed PMID: 22923871; PubMed Central PMCID: PMC3425070.
<br>
8: Hacioğlu F, Onal A. Determination of eprosartan mesylate and
hydrochlorothiazide in tablets by derivative spectrophotometric and
high-performance liquid chromatographic methods. J Chromatogr Sci. 2012
Sep;50(8):688-93. doi: 10.1093/chromsci/bms037. Epub 2012 May 10. PubMed PMID:
22576732.
<br>
9: Qian JJ, Hu XR, Gu J, Wu SX. Eprosartan mesylate, an angiotensin II receptor
antagonist. Acta Crystallogr Sect E Struct Rep Online. 2011 Apr 1;67(Pt
4):o770-1. doi: 10.1107/S1600536811006659. Epub 2011 Mar 2. PubMed PMID:
21754064; PubMed Central PMCID: PMC3099799.
<br>
10: Teitelbaum I, Chilvers M, Reiz RJ. The angiotensin receptor blocker
eprosartan mesylate reduces pulse pressure in isolated systolic hypertension. Can
J Cardiol. 2004 Oct;20 Suppl C:11C-16C. PubMed PMID: 16807618.
|